Cargando…
Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk
There is an increasing expectation that computational approaches may supplement existing human decision-making. Frontloading of models for cardiac safety prediction is no exception to this trend, and ongoing regulatory initiatives propose use of high-throughput in vitro data combined with computatio...
Autores principales: | Davies, Mark R., Martinec, Michael, Walls, Robert, Schwarz, Roman, Mirams, Gary R., Wang, Ken, Steiner, Guido, Surinach, Andy, Flores, Carlos, Lavé, Thierry, Singer, Thomas, Polonchuk, Liudmila |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659582/ https://www.ncbi.nlm.nih.gov/pubmed/33205069 http://dx.doi.org/10.1016/j.xcrm.2020.100076 |
Ejemplares similares
-
Recent developments in using mechanistic cardiac modelling for drug safety evaluation
por: Davies, Mark R., et al.
Publicado: (2016) -
Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing
por: Mirams, Gary R, et al.
Publicado: (2012) -
Early afterdepolarisation tendency as a simulated pro-arrhythmic risk indicator
por: McMillan, Beth, et al.
Publicado: (2017) -
Omega-3 Fatty Acids: Anti-Arrhythmic, Pro-Arrhythmic, or Both?
por: von Schacky, C.
Publicado: (2012) -
Comprehensive in vitro pro‐arrhythmic assays demonstrate that omecamtiv mecarbil has low pro‐arrhythmic risk
por: Qu, Yusheng, et al.
Publicado: (2021)